Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
You may also be interested in...
The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor.
Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.
Amgen reported a 6% year-over-year increase in second quarter sales despite pandemic-related declines for several drugs as newer product gains and Otezla righted a rocky ship.